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Abstract 
Methods
Zika Virus (ZIKV) has been thought to cause 
microcephaly in infants of infected mothers, 
because fetal neural stem cell death has been 
shown to be mediated by the virus. Since it is 
known that neural stem and brain tumor cells 
possess similar properties, we explored the 
feasibility of utilizing ZIKV as an oncolytic virus 
against human brain tumors. Specifically, we sought 
to characterize ZIKV infectivity in the 
medulloblastoma cell line (DAOY), as this cancer is 
the most prevalent amongst children and has been 
proven difficult to treat through chemotherapy, 
radiation, and surgical procedures. DAOY cells 
were incubated with ZIKV for 3 days, and RNA was 
isolated and used for qRT-PCR. Envelope, NS2, 
and NS5 proteins characteristic of the virus 
demonstrated a fold change of 10,000 or greater, 
indicating high viral infectivity. ZIKV presence within 
DAOY cells was also observed by 
immunocytochemistry. Viral kinetics were further 
assessed by means of a viral plaque assay. We 
observed an absence of plaques, indicating that 
ZIKV may not be released from infected cells. Thus, 
ZIKV could be better used as an adjuvant in 
stimulating the immune system for tumor targeting 
rather than as a solely oncolytic virus. We then 
tested the ability for ZIKV to act as an adjuvant in a 
murine model of glioma (GL261). Results 
demonstrated increased survival of mice injected 
with ZIKV in conjunction with a vaccine 
immunotherapy as compared to those only injected 
with ZIKV. These results provide support for the 
potential of ZIKV as a mechanism in 
medulloblastoma-targeted treatment.
Conclusions and Future Directions
• DAOY cells were grown on Fibronectin chamber 
slides and stained for AXL, TIM-1, DC-SIGN, and 
Tyro3 receptors
• DAOY cells were incubated with ZIKV for 3 days 
at an MOI of 0.5
• RNA was then isolated from infected and control 
cells and used for two-step RT-qPCR
• Primers tested for AXL, MERTK, and TYRO3 
receptors as well as ZKV envelope, NS2, and 
NS5 gene expression
• cDNA obtained from RT-qPCR was analyzed by 
gel electrophoresis
Together, these results provide further evidence for 
eradication and treatment of the human 
medulloblastoma using ZKV: 
• AXL, TIM-1, MERTK, and TYRO3 receptors 
characteristic of ZKV-targeted neural stem cells are 
present in DAOY cells
• DAOY demonstrates high infectivity after 3 days of 
exposure to ZKV
• Further analysis of ZKV kinetics in DAOY will be 
explored through viral plaque assay
• Apoptosis and cell death can be identified in DAOY 
cells by flow cytometry staining for Caspase 3 
• Transcriptome analysis of RNA-Seq data will be 
used to explore mechanisms of ZKV infection in 
DAOY cells
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Figure 2. Presence of ZKV Entry Receptors in DAOY through RT-qPCR
Results indicate relative differences in fold change between control and 3 day ZKV-infected DAOY cells for Axl, 
MERTK, and Tyro3 receptors. For Axl and MERTK receptors, fold change decreased from uninfected to 3 days post 
infection. Conversely, the fold change in Tyro3 significantly increased from the time of infection.
Figure 1. Presence of Receptors in DAOY cells by Immunohistochemistry
Suggested cell entry receptors were stained by immunohistochemistry and identified in DAOY.
Figure 6. Validation of DAOY ZKV Infection 
Control and 3 day ZKV-infected cDNA samples were run in triplicate on 
2% agarose gel. Envelope, NS2, and NS5 genes characteristic of ZKV 
fluoresce, indicating infection.
Figure 5. High ZKV 
Infectivity Characterized 
through RT-qPCR
Proteins characteristic of 
ZKV are present in DAOY 
cells, with a fold change of 
10,000 and greater 
between uninfected and 
infected cells. 
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GL261 in vivo Studies
Figure 3. Survival Curves of in vivo murine models
A. ZIKV has a modest oncolytic effect against GL261 implanted tumors
B. Tumor vaccines with ZIKV adjuvants increase survival of GL261 tumor implanted mice
Figure 4. Viral Kinetics Assessed by Plaque Assay
A. Vero positive controls used to determine viral concentration in terms of infectious dose. Number of plaque   
B. GL261 plaque assay demonstrates an absence of plaques, indicating ZIKV particles are not released from the 
host cell during replication
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